格隆汇1月29日丨中国通号(03969.HK)公告，2025年11月至12月，公司共中标二十一个重要项目，其中 在铁路市场中标八个重要项目，分别为广州东站改造及广州东至新塘五六线WLXSG7标段项目，中标 金额人民币4.08亿元；白阿铁路乌兰浩特至阿尔山扩能改造工程BASG-3标段项目，中标金额人民币3.6 亿元；沪苏锡常城际铁路太仓先导段"四电"工程、房建和装饰装修工程SXC-CJTL-SG7-1标段项目，中 标金额人民币3.47亿元；成达万弱电工程项目信号轨道设备联合招标采购项目，中标金额人民币2.64亿 元； 长春市轨道交通4号线站台门加装及信号系统升级等配套升级改造项目–信号及站台门系统设备采购项 目，中标金额人民币1.88亿元；2026–2028年上海轨道交通6、7、9、11、15、16、18号线通号设备委外 维护项目，中标金额人民币1.86亿元；北京轨道交通亦庄线台湖车辆段增设站点工程施工总承包项目， 中标金额人民币1.47亿元；沙特利雅得KAFD单轨系统总包项目机电安装工程项目，中标金额人民币 1.46亿元；上海市轨道交通15号线南延伸工程信号系统采购项目，中标金额人民币1.45亿元；北京地铁 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 中 國 鐵 路 通 信 信 號 股 份 有 限 公 司 China Railway Signal & Communication Corporation Limited* （在中華人民共和國註冊成立的股份有限公司） （股份代號：3969） 軌道交通市場重要項目中標公告 中 國 鐵 路 通 信 信 號 股 份 有 限 公 司（「本公司」）根 據《香 港 聯 合 交 易 所 有 限 公 司 證 券 上 市 規 則》（「上市規則」）第13.09條、第13.10B條及香港法例第571 章《證 券 及 期 貨 條 例》第XIVA部 項 下 之 內 幕 消 息 條 文（按 上 市 規 則 定 義）作 出 本 公 告。 2025年11月 至12月，本 公 司 共 中 標 二 十 一 個 重 要 項 目，其 中 在 鐵 路 市 場 中 標 八 個 重 ...

Group 1 - Meinian Health plans to participate in the restructuring of Zhejiang Bangjie Holdings, aiming to become the controlling shareholder after the completion of the restructuring [3] - Baiyin Nonferrous Metals reported that the revenue from gold and silver products accounted for a low proportion of total operating income, with gold sales contributing 18.67% and silver sales 4.54% in the first half of 2025 [4] - Tiens Wind Power decided to implement a long-term production suspension for six wholly-owned subsidiaries to optimize resource allocation and focus on core businesses [5] Group 2 - Tongling Nonferrous Metals indicated significant uncertainty in the price fluctuations of its main products, with a low self-sufficiency rate for copper concentrate posing supply stability risks [6] - *ST Aowei received a notice of termination of listing due to its market capitalization falling below 500 million yuan for twenty consecutive trading days [7] - Foton Motor expects a net profit increase of approximately 1551% year-on-year for 2025, driven by sales growth in new energy vehicles and overseas markets [9] Group 3 - Beimo High-tech anticipates a net profit increase of 1076.16% to 1261.87% for 2025, supported by cost control and reduced credit impairment losses [10] - Zhongke Sanhuan forecasts a net profit growth of 566.23% to 899.35% for 2025, attributed to technological innovation and improved operational efficiency [12] - Wancheng Group expects a net profit increase of 222.38% to 266.94% for 2025, driven by growth in its retail business and improved sales margins [13] Group 4 - Huayi Technology anticipates a net profit increase of 191.52% to 330.34% for 2025, benefiting from product optimization and cost reduction measures [14] - Nanmo Biology expects a net profit growth of 269.49% to 423.44% for 2025, supported by increased revenue in the biopharmaceutical sector and improved cost control [15] - Baiao Saitu forecasts a net profit increase of 384.26% to 443.88% for 2025, driven by expansion in overseas markets and recovery in the domestic biopharmaceutical industry [16] Group 5 - Hailanxin expects a net profit increase of 387.47% to 631.2% for 2025, supported by advancements in technology and increased market share in marine observation [17] - Panjiang Co. anticipates a net profit growth of 205.3% to 264.83% for 2025, driven by increased coal production and reduced costs [18] - Huaguang New Materials expects a net profit increase of 104.67% to 141.88% for 2025, with significant growth in the electronic sector [20] Group 6 - Guo Sheng Securities forecasts a net profit increase of 25.44% to 67.25% for 2025, supported by active capital market participation and growth in various business segments [25] - Shengyi Technology expects a net profit growth of 87% to 98% for 2025, driven by increased sales of copper-clad laminates [26] - Sifutian anticipates a net loss of 30 million to 45 million yuan for 2025, although this represents a significant reduction in losses compared to the previous year [27] Group 7 - Maanshan Steel expects a net loss of 1.9 billion to 2.5 billion yuan for 2025, with a substantial reduction in losses compared to the previous year [28] - Shennong Seed Industry forecasts a net profit of 90 million to 120 million yuan for 2025, marking a turnaround from previous losses [30] - Jifeng Co. anticipates a net profit of 410 million to 495 million yuan for 2025, achieving a turnaround from losses [31]

Earnings Forecasts - Shengyi Electronics expects a net profit of 1.431 billion to 1.513 billion yuan in 2025, an increase of 331.03% to 355.88% year-on-year [1] - Tigermed anticipates a net profit of 830 million to 1.23 billion yuan in 2025, representing a growth of 105% to 204% year-on-year [2] - Shunbo Alloy forecasts a net profit of 210 million to 270 million yuan in 2025, with an increase of 222.96% to 315.23% year-on-year [3] - Jinkong Electric expects a net profit of 155 million to 195 million yuan in 2025, reflecting a growth of 383.21% to 507.9% year-on-year [9] - Baiao Saitu anticipates a net profit of 162 million to 182 million yuan in 2025, with a year-on-year increase of 384.26% to 443.88% [18] - Panjiang Co. expects a net profit of 318 million to 380 million yuan in 2025, representing a growth of 205.30% to 264.83% year-on-year [38] Loss Forecasts - Liaoning Energy predicts a net loss of 273 million to 410 million yuan in 2025, compared to a profit of 202 million yuan in the previous year [5] - Anbotong anticipates a net loss of 114 million to 165 million yuan in 2025, with a revenue decrease of 19.65% to 27.25% [7] - Wantai Bio forecasts a net loss of 330 million to 410 million yuan in 2025, compared to a profit of 106 million yuan in the previous year [12] - Xingyun Co. expects a net loss of 155 million to 230 million yuan in 2025, compared to a loss of 82.44 million yuan in the previous year [20] - Huaxing Co. anticipates a net loss of 800 million to 1.2 billion yuan in 2025, with a reduction in loss compared to 1.67 billion yuan in the previous year [46] New Product Approvals - Hengrui Medicine received acceptance for a new indication application for its innovative drug, combining Carrelizumab and Apatinib for treating unresectable liver cancer [4] - Tianen Kang's subsidiary received a drug registration acceptance notice for Lidocaine and Prilocaine aerosol [31] - Lisheng Pharmaceutical announced that its Aminophylline tablets passed the consistency evaluation for generic drugs [40] Share Buyback Plans - Hengyuan Coal Power plans to repurchase shares with a total amount not less than 200 million yuan and not exceeding 250 million yuan [13] Contract Wins - China Communication Signal Co. won contracts totaling approximately 5.26 billion yuan for 21 important projects in the railway and urban rail transit markets [37]

证券代码：688009 证券简称：中国通号 公告编号：2026-004 中国铁路通信信号股份有限公司 关于自愿披露轨道交通市场重要项目中标的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 中标共计二十一个重要项目，其中铁路市场八个，分别为广州东站改造 及广州东至新塘五六线WLXSG7标段项目，中标金额4.08亿元；白阿铁路乌兰 浩特至阿尔山扩能改造工程BASG-3标段项目，中标金额3.6亿元；沪苏锡常 城际铁路太仓先导段"四电"工程、房建和装饰装修工程SXC-CJTL-SG7-1标 段项目，中标金额3.47亿元；成达万弱电工程项目信号轨道设备联合招标采 购项目，中标金额2.64亿元；新建合浦至湛江铁路（广东段）"三电"及管 线迁改工程HZGDQG-2标项目，中标金额2.35亿元；2025年中国铁路上海局集 团有限公司300T型ATP车载设备高级修项目，中标金额1.44亿元；石太客专 联锁列控及通信系统大修工程STDX-1标段项目，中标金额1.4亿元；新建成 都至达州至万州高速铁路无线闭塞中心RBC（含 ...

格隆汇1月29日丨中国通号(688009.SH)公布，2025年11月至12月，公司中标共计二十一个重要项目，其 中铁路市场八个，城市轨道交通市场十三个。本次公告中标项目详细情况如下： 中标共计二十一个重要项目，其中铁路市场八个，分别为广州东站改造及广州东至新塘五六线 WLXSG7标段项目，中标金额4.08亿元；白阿铁路乌兰浩特至阿尔山扩能改造工程BASG-3标段项目， 中标金额3.6亿元；沪苏锡常城际铁路太仓先导段"四电"工程、房建和装饰装修工程SXC-CJTL-SG7-1标 段项目，中标金额3.47亿元；成达万弱电工程项目信号轨道设备联合招标采购项目，中标金额2.64亿 元；新建合浦至湛江铁路（广东段）"三电"及管线迁改工程HZGDQG-2标项目，中标金额2.35亿元； 2025年中国铁路上海局集团有限公司300T型ATP车载设备高级修项目，中标金额1.44亿元；石太客专联 锁列控及通信系统大修工程STDX-1标段项目，中标金额1.4亿元；新建成都至达州至万州高速铁路无线 闭塞中心RBC（含列控中心、计算机联锁、临时限速服务器、无线闭塞中心RBC）采购项目，中标金 额1.21亿元。城市轨道交通市场十三个， ...

南财智讯1月29日电，中国通号公告，公司于2025年11月至12月中标共计二十一个重要项目，其中铁路 市场八个，城市轨道交通市场十三个。铁路市场项目包括：广州东站改造及广州东至新塘五六线 WLXSG7标段项目，中标金额4.08亿元；白阿铁路乌兰浩特至阿尔山扩能改造工程BASG-3标段项目， 中标金额3.60亿元；沪苏锡常城际铁路太仓先导段"四电"工程、房建和装饰装修工程SXC-CJTL-SG7-1 标段项目，中标金额3.47亿元；成达万弱电工程项目信号轨道设备联合招标采购项目，中标金额2.64亿 元；新建合浦至湛江铁路（广东段）"三电"及管线迁改工程HZGDQG-2标项目，中标金额2.35亿元； 2025年中国铁路上海局集团有限公司300T型ATP车载设备高级修项目，中标金额1.44亿元；石太客专联 锁列控及通信系统大修工程STDX-1标段项目，中标金额1.40亿元；新建成都至达州至万州高速铁路无 线闭塞中心RBC（含列控中心、计算机联锁、临时限速服务器、无线闭塞中心RBC）采购项目，中标 金额1.21亿元。城市轨道交通市场项目包括：市域(郊)铁路成都至眉山线信号系统集成采购与施工总承 包项目，中标金额5.7 ...

每经AI快讯，1月29日，中国通号(688009.SH)公告称，公司在2025年11月至12月中标共计二十一个重要 项目，其中铁路市场八个，城市轨道交通市场十三个。项目中标金额总计约为人民币52.6亿元，约占公 司中国会计准则下2024年经审计营业收入的16.20%。 ...

格隆汇1月29日｜中国通号公告，公司于2025年11月至12月中标21个重要轨道交通项目，总金额为52.6 亿元。其中，铁路市场包括广州东站改造项目，金额4.08亿元；白阿铁路扩能改造项目，金额3.6亿元； 沪苏锡常城际铁路太仓项目，金额3.47亿元等。城市轨道交通市场中标项目包括成都至眉山线项目，金 额5.76亿元；上海轨道交通19号线项目，金额4.5亿元等。上述项目中标金额约占公司2024年经审计营业 收入的16.20%。项目的顺利实施预计将对公司产生积极影响。 ...

Core Viewpoint - The railway transportation equipment sector experienced a decline of 0.39% on January 28, with Dinghan Technology leading the losses, while the overall Shanghai Composite Index rose by 0.27% [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4151.24, up 0.27% [1]. - The Shenzhen Component Index closed at 14342.9, up 0.09% [1]. - The railway transportation equipment sector saw significant individual stock movements, with Jinchuan Heavy Industry rising by 10.01% to a closing price of 17.37 [1]. Group 2: Stock Performance - Major gainers in the railway equipment sector included: - Jinchuan Heavy Industry: 10.01% increase, closing at 17.37, with a trading volume of 153,600 shares and a turnover of 253 million [1]. - Kyushu One Rail: 6.16% increase, closing at 23.77, with a trading volume of 52,400 shares and a turnover of 123 million [1]. - China Railway Materials: 4.21% increase, closing at 2.97, with a trading volume of 2.7 million shares and a turnover of 797 million [1]. - Major decliners included: - Dinghan Technology: 4.49% decrease, closing at 8.51, with a trading volume of 222,700 shares and a turnover of 192 million [2]. - Tianyi New Materials: 4.32% decrease, closing at 8.20, with a trading volume of 238,600 shares and a turnover of 197 million [2]. Group 3: Capital Flow - The railway transportation equipment sector saw a net outflow of 800 million from institutional investors, while retail investors contributed a net inflow of 244 million [2]. - Notable capital flows included: - China Railway Materials: 127 million net inflow from institutional investors, but a net outflow of 99.6 million from retail investors [3]. - Jinchuan Heavy Industry: 34.59 million net inflow from institutional investors, with a net outflow of 25.88 million from retail investors [3].